PT  - JOURNAL ARTICLE
AU  - Lu, Yong
AU  - Han, Kun
AU  - Xue, Gang
AU  - Zheng, Ningbo
AU  - Jin, Guangxu
TI  - Estimated Spike Evolution and Impact of Emerging SARS-CoV-2 Variants
AID  - 10.1101/2021.05.06.21256705
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.06.21256705
4099  - http://medrxiv.org/content/early/2021/05/10/2021.05.06.21256705.short
4100  - http://medrxiv.org/content/early/2021/05/10/2021.05.06.21256705.full
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, has been mutating and thus variants emerged. This suggests that SARS-CoV-2 could mutate at an unsteady pace. Supportive evidence comes from the accelerated evolution which was revealed by tracking mutation rates of the genomic location of Spike protein. This process is sponsored by a small portion of the virus population but not the largest viral clades. Moreover, it generally took one to six months for current variants that caused peaks of COVID-19 cases and deaths to survive selection pressure. Based on this statistic result and the above speedy Spike evolution, another upcoming peak would come around July 2021 and disastrously attack Africa, Asia, Europe, and North America. This is the prediction generated by a mathematical model on evolutionary spread. The reliability of this model and future trends out of it comes from the comprehensive consideration of factors mainly including mutation rate, selection course, and spreading speed. Notably, if the prophecy is true, then the new wave will be the first determined by accelerated Spike evolution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the support of the Wake Forest Baptist Comprehensive Cancer Center Bioinformatics Shared Resource, supported by P30CA012197.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:exemptionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SARS-CoV-2 genomic sequences are from GISAID (https://www.gisaid.org/). https://www.gisaid.org/